A Randomised, Double-blind, Placebo-controlled Phase IIa Study to Assess the Pharmacodynamics, Safety, and Pharmacokinetics of AZD4901 When Given in Multiple Doses to Females With Polycystic Ovary Syndrome
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science
Change from baseline at Day 7 in Luteinizing hormone AUC(0-8)
Day-1 and Day7
No
Jyothis George, MD
Principal Investigator
University of Edinburgh
United Kingdom: Medicines and Healthcare Products Regulatory Agency
D5320C00001
NCT01872078
June 2013
March 2014
Name | Location |
---|